Key result
Prasugrel or ticagrelor did not reduce the adjusted rate of one-year mortality compared to clopidogrel in patients with acute myocardial infarction complicated by cardiogenic shock.
Why the study?
Does prasugrel or ticagrelor reduce one-year mortality compared to clopidogrel in patients with acute myocardial infarction complicated by cardiogenic shock?
Observational (n=483)
Open-label
None
Yes
Does prasugrel or ticagrelor reduce one-year mortality compared to clopidogrel in patients with acute myocardial infarction complicated by cardiogenic shock?
In patients with AMI complicated by cardiogenic shock, potent P2Y12 inhibitors (prasugrel or ticagrelor) are feasible and not associated with increased bleeding or mortality compared to clopidogrel, though superiority remains unproven.
Answers are grounded in this paper and cite their sources.
No mortality benefit seen with potent P2Y12 inhibitors; this observational result leaves open the optimal regimen in AMI cardiogenic shock.
AIMS: The aim of this post hoc subgroup analysis of the Intraaortic Balloon Pump in Cardiogenic Shock II trial was to compare the clinical outcome of patients treated with either clopidogrel or the newer, more potent P2Y12 receptor inhibitors prasugrel or ticagrelor. METHODS AND RESULTS: The primary endpoint was one-year mortality with respect to different P2Y12 receptor inhibitors. Secondary safety endpoints were GUSTO bleedings until hospital discharge. After exclusion of 117 patients (patients who died before or during PCI, patients with unavailable information on P2Y12 receptor inhibitor treatment, patients not receiving or receiving a combination of different P2Y12 receptor inhibitors as acute antiplatelet therapy), 483 patients were analysed. Of these, 373 patients (77.2%) received clopidogrel and 110 patients (22.8%) either prasugrel or ticagrelor as acute antiplatelet therapy. The adjusted rate of mortality did not differ between prasugrel/ticagrelor and clopidogrel treated patients (HR: 0.83, 95% CI: 0.59-1.19, padj=0.31). GUSTO bleedings did not differ between groups (14.3% for prasugrel/ticagrelor and 16.4% for clopidogrel, HR: 0.91, 95% CI: 0.55-1.5, padj=0.7). CONCLUSIONS: This IABP-SHOCK II trial subgroup analysis shows that the use of potent P2Y12 receptor inhibitors like prasugrel or ticagrelor is feasible and might not be harmful in selected patients with cardiogenic shock complicating acute myocardial infarction. However, the superiority in comparison to clopidogrel remains to be proven.
No takes yet. Share an insight, caveat, or question.
Orban et al. (2016) conducted an observational in Acute myocardial infarction complicated by cardiogenic shock (n=483). Prasugrel or ticagrelor vs. Clopidogrel was evaluated on One-year mortality (HR 0.83, 95% CI 0.59-1.19, p=0.31). Prasugrel or ticagrelor did not reduce the adjusted rate of one-year mortality compared to clopidogrel in patients with acute myocardial infarction complicated by cardiogenic shock.
Synapse has enriched 10 related papers. Consider them for comparative context: